Validation of CHK1 and BRD4 inhibitors, AZD7762 and OTX‐015, respectively, in three HCC‐PDXO lines have demonstrated that this combination exhibits synergistic interactions only in MYCHi HCC‐PDXOs. Here, CHEK1 is linked to hepatocellular carcinoma.